Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.

Greenwich LifeSciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

STAFFORD, TEXAS, AUG. 13, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY ANNOUNCED THE ADDITION OF CLINICAL SITES IN ROMANIA.

GREENWICH LIFESCIENCES ANNOUNCES EXPANSION OF FLAMINGO-01 INTO ROMANIA

STAFFORD, TEXAS, AUG. 11, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT OF GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES IN PATIENTS WHO HAVE PREVIOUSLY UNDERGONE SURGERY, TODAY PROVIDED THE FOLLOWING UPDATE ON CEO INTERVIEWS AND CORPORATE EVENTS.

GREENWICH LIFESCIENCES PROVIDES UPDATE ON CEO INTERVIEWS & CORPORATE EVENTS

STAFFORD, TEXAS, APRIL 03, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY PROVIDED THE FOLLOWING GLOBAL UPDATE ON FLAMINGO-01. FLAMINGO-01 PROGRESS TO DATE & FUTURE PLANS THE COMPANY RECENTLY CONFIRMED THAT THE PRELIMINARY HLA PREVALENCE, SAFETY, AND IMMUNE RESPONSE DATA IN FLAMINGO-01 PATIENTS IS TRENDING AS EXPECTED IN BOTH HLA-A*02 AND NON-HLA-A*02 ARMS.

GREENWICH LIFESCIENCES PROVIDES GLOBAL UPDATE ON FLAMINGO-01

STAFFORD, TEXAS, APRIL 02, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY ANNOUNCED THE FOLLOWING UPDATE ON FLAMINGO-01 OPEN LABEL IMMUNE RESPONSE DATA.

GREENWICH LIFESCIENCES ANNOUNCES POSITIVE IMMUNE RESPONSE DATA FROM FLAMINGO-01 PHASE III CLINICAL TRIAL

STAFFORD, TEXAS, MARCH 27, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS EXTENDED THE LOCK-UP OF THE SHARES OWNED BY THE COMPANY'S DIRECTORS, OFFICERS, AND EXISTING PRE-IPO INVESTORS TO MARCH 31, 2026 WHICH IS APPROXIMATELY 66 MONTHS FROM DATE OF THE COMPANY'S IPO. DURING THIS PERIOD, CURRENT OFFICERS, DIRECTORS AND CERTAIN SHAREHOLDERS WILL NOT BE ABLE TO SELL THEIR SHARES OF THE COMPANY'S COMMON STOCK UNLESS OTHERWISE MODIFIED BY THE BOARD OF DIRECTORS. AFTER MARCH 31, 2026, THE QUANTITY OF THESE LOCKED-UP SHARES THAT CAN BE SOLD DAILY AND OVER VARIOUS PERIODS OF TIME WILL BE RESTRICTED UNLESS OTHERWISE MODIFIED BY THE BOARD OF DIRECTORS.

GREENWICH LIFESCIENCES EXTENDS LOCK-UP OF DIRECTORS AND OFFICERS TO MARCH 31, 2026

STAFFORD, TEXAS, MARCH 17, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY ANNOUNCED THE FOLLOWING UPDATE ON FLAMINGO-01 OPEN LABEL SAFETY DATA.

GREENWICH LIFESCIENCES PROVIDES UPDATE ON OPEN LABEL SAFETY DATA FROM FLAMINGO-01

STAFFORD, TEXAS, FEB. 10, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY ANNOUNCED THE FOLLOWING UPDATE ON FLAMINGO-01 OPEN LABEL HLA DATA.

GREENWICH LIFESCIENCES PROVIDES UPDATE ON OPEN LABEL HLA DATA FROM FLAMINGO-01

STAFFORD, TEXAS, JAN. 29, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY PROVIDED THE FOLLOWING UPDATE ON THE EXPANSION OF THE CLINICAL TRIAL INTO EUROPE.

GREENWICH LIFESCIENCES APPROVED TO ADD ADDITIONAL SITES TO FLAMINGO-01 IN EUROPE

STAFFORD, TEXAS, JAN. 27, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY ANNOUNCED THE ACTIVATION OF CLINICAL SITES IN POLAND.

GREENWICH LIFESCIENCES ANNOUNCES ACTIVATION OF FLAMINGO-01 IN POLAND

STAFFORD, TEXAS, JAN. 23, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY ANNOUNCED THE INITIATION OF NEW CLINICAL SITES IN THE US.

GREENWICH LIFESCIENCES ANNOUNCES ADDITIONS OF HARVARD AND JOHNS HOPKINS TO FLAMINGO-01

STAFFORD, TEXAS, JAN. 22, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY PROVIDED THE FOLLOWING UPDATE ON THE COMMERCIAL MANUFACTURING OF GP2.

GREENWICH LIFESCIENCES PROVIDES UPDATE ON COMMERCIAL MANUFACTURING

STAFFORD, TEXAS, JAN. 14, 2025 (GLOBE NEWSWIRE) -- GREENWICH LIFESCIENCES, INC. (NASDAQ: GLSI) (THE "COMPANY"), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON ITS PHASE III CLINICAL TRIAL, FLAMINGO-01, WHICH IS EVALUATING GLSI-100, AN IMMUNOTHERAPY TO PREVENT BREAST CANCER RECURRENCES, TODAY ANNOUNCED THE INITIATION OF CLINICAL SITES IN GERMANY.

Greenwich LifeSciences, Inc.

GLSI

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Greenwich LifeSciences, Inc.

GLSI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

GLSI